Devyser offers diagnostic kits for complex DNA testing within oncology, reproductive health and hereditary diseases. Their products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in a wide array of genetic tests.


JSI developed customized software plug-in for all Devyser NGS products, including Devyser BRCA / Devyser CFTR for NGS.

Pre-defined files are available for import in SeqNext. These contain all settings, such as regions of interest and validated analysis settings for mutation analysis including CNV detection.


Ulf Klangby, CEO and co-founder of Devyser, says, “Being able to offer our NGS kits to users of JSI’s software platform is a fantastic opportunity for us. JSI’s reputation of being at the forefront of bio-informatic platform development is completely aligned with our own philosophy of meeting the needs of the routine diagnostic lab, in this case those with full analytic capacity in-house.”

Joachim Strub, CEO of JSI Medical Systems, comments, “We are excited to enable a robust NGS solution together with Devyser. This will empower our customers and future users of the JSI platform to maintain full control of their analytical processes and results using the latest NGS technology.”

Download full press release.